Biodesix presents on lung cancer guidance tests at IASLC 2023

Biodesix announced that two abstracts will be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Lung Conference on Lung Cancer. The first presentation showcases a new analysis of the large multi-center observational registry study INSIGHT demonstrating the ability of the VeriStrat host immune classifier to predict response to immune checkpoint inhibitor regimens in patients with advanced stage non-small cell lung cancer. The INSIGHT trial, which recently reached its enrollment goal of 5,000 patients with NSCLC, previously yielded data showing that patients with greater than or equal to50% PD-L1 status classified as Host Immune Classifier Cold, also known as VeriStrat Poor, had superior median overall survival when receiving ICI plus chemotherapy versus ICI alone. The expanded analysis confirms these findings and concludes that patients with less than50% PD-L1 status classified as Host Immune Classifier Hot, also known as VeriStrat Good, had comparable overall survival when receiving either ICI alone or in combination with chemotherapy. The second presentation details the performance of a pre-surgical, blood-based Risk of Recurrence test in three independent cohorts. Patients with early stage lung cancer have favorable outcomes, but many of these patients experience a recurrence which results in a poor prognosis. The test was designed to identify patients with a high probability of recurrence that could be considered for more aggressive treatment or enhanced surveillance. This initial validation study evaluated nearly 800 patients with Stage I NSCLC and demonstrated the test’s ability to stratify three distinct groups of patients based on their proteomic profile with high, intermediate, or low risk of recurrence. Furthermore, incorporating the adenocarcinoma grade, a conventional risk factor for recurrence, improved the performance of the test.